IMNM
Immunome, Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables): amplitud de titulares 0.0% · flujo de acciones +24.9% · nuevas posiciones netas 0.0% · fórmula
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | +1 | 68.26M | $1.45B | +7 | −7 |
| Q1 2026 | 85 | +8 | 69.87M | $1.52B | +12 | −4 |
| Q4 2025 | 77 | -1 | 71.18M | $1.53B | n/a | −1 |
| Q3 2025 | 17 | 0 | 44.21M | $517.66M | +1 | −1 |
| Q2 2025 | 14 | -2 | 33.29M | $309.62M | n/a | −2 |
| Q1 2025 | 13 | 0 | 18.78M | $126.42M | +1 | −1 |
| Q4 2024 | 13 | +3 | 9.20M | $97.76M | +3 | n/a |
| Q3 2024 | 9 | -2 | 5.86M | $85.63M | n/a | −2 |
| Q2 2024 | 11 | n/a | 5.95M | $72.02M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 13.06M | +111.7% | $152.89M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (pasivo) | 5.82M | +0.9% | $68.18M | 0.0% | ▲ Add | 2 | SEC ↗ ×10 |
| 3 | The Vanguard Group ✦ (pasivo) | 4.89M | +8.2% | $57.30M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 4 | Point72 Asset Management ✦ | 4.82M | +3.0% | $56.49M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 3.74M | +25.5% | $43.83M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | PRIMECAP Management ✦ | 3.02M | -0.1% | $35.34M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 7 | State Street Global Advisors ✦ (pasivo) | 2.80M | +11.2% | $32.83M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (pasivo) | 1.89M | +1.8% | $22.19M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Morgan Stanley ✦ | 1.83M | n/a | $21.47M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 10 | Citadel Advisors ✦ | 841.14K | Nuevo | $9.85M | 0.0% | New | 1 | SEC ↗ ×2 |
| 11 | Marshall Wace ✦ | 692.18K | -46.7% | $8.11M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 12 | Wellington Management ✦ | 254.07K | +19.9% | $2.98M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 13 | Goldman Sachs Group ✦ | 208.95K | n/a | $2.45M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Renaissance Technologies ✦ | 202.30K | +103.6% | $2.37M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | JPMorgan Chase ✦ | 65.21K | n/a | $763,562 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 16 | Millennium Management ✦ | 41.88K | -63.1% | $490,462 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 10.20K | 0.0% | $119,442 | 0.0% | Held | 3 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Citadel Advisors | $9.85M | 0.0% |
Posición cerrada
| Two Sigma Investments | $247,882 | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1 tenedores, 35.50K acciones, $776 declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 13.20K acc. · $334,224
Director · 11.05K acc. · $301,058
Director · 62.29K acc. · $1.63M
Director · 10.12K acc. · $263,959
Director · 15.25K acc. · $397,363
Director · 20.84K acc. · $543,090
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología